<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of <z:e sem="disease" ids="C0005956" disease_type="Disease or Syndrome" abbrv="">bone marrow disorders</z:e> characterized by ineffective hematopoiesis and a tendency to develop <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In some patients, laboratory and clinical evidence supports a role for the immune system in the pathogenesis of early <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Many younger patients who respond to immunosuppressive therapy with drugs such as antithymocyte globulin and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> have clonal expansions of cytotoxic CD8(+) T cells that suppress <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis, as well as expansion of CD4(+) helper T-cell subsets that promote and sustain <z:hpo ids='HP_0002960'>autoimmunity</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Immunosuppressive therapy can produce hematologic responses in some patients and may improve survival and halt leukemic progression </plain></SENT>
<SENT sid="4" pm="."><plain>In this report, we describe a 56-year-old woman who presented with <z:mp ids='MP_0002899'>fatigue</z:mp> and <z:hpo ids='HP_0000978'>easy bruising</z:hpo>, eventually became pancytopenic, and was diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>After treatment with a clinical protocol using alemtuzumab, an anti-CD52 antibody, her blood cell counts returned to <z:mpath ids='MPATH_458'>normal</z:mpath> and she has remained in complete remission for more than 2 years of follow-up </plain></SENT>
<SENT sid="6" pm="."><plain>In this article, we review the pathobiology of <z:hpo ids='HP_0002958'>immune dysregulation</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and summarize the role of immunosuppressive therapy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>